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Abstract 
The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization 
workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept 
of multi‑morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used glob‑
ally for all countries and populations. ARIA—disseminated and implemented in over 70 countries globally—is now 
focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA 
(Contre les Maladies Chroniques pour un Vieillissement Actif)‑ARIA Sentinel NetworK] uses mobile technology to develop 
care pathways for the management of rhinitis and asthma by a multi‑disciplinary group and by patients themselves. 
An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symp‑
tom control and work productivity as well as a clinical decision support system. It is associated with an inter‑operable 
tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the 
European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an 
active and healthy life to rhinitis sufferers, whatever their age, sex or socio‑economic status, in order to reduce health 
and social inequalities incurred by the disease.
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Background
The Allergic Rhinitis and its Impact on Asthma (ARIA) 
initiative commenced during a World Health Organiza-
tion (WHO) workshop in 1999 (published in 2001) [1]. 
The goals were (1) to propose a new allergic rhinitis (AR) 
classification using persistence and severity of symp-
toms in order to more closely reflect patients’ needs, (2) 
to promote the concept of multi-morbidity in asthma 
and rhinitis as a key factor for patient management, (3) 
to develop guidelines with all stakeholders, (4) to include 
experts from developed and developing countries and (5) 
to initiate global implementation among health care pro-
fessionals (HCPs) and patients.
Patients, clinicians and other HCPs are confronted 
with various treatment choices for the management of 
AR. This contributes to considerable variation in clinical 
practice. Worldwide, patients, clinicians and other HCPs 
are faced with uncertainty about the relative merits and 
downsides of the many AR treatment options available. 
The first ARIA workshop report used the Shekelle evi-
dence-based methodology [1, 2]. It was the first guideline 
in chronic disease to assess multi-morbid conditions (i.e. 
asthma and rhinitis in the same patient). In 2008, ARIA 
was updated using the same evidence-based system [3]. 
More transparent reporting of guidelines to facilitate 
understanding and acceptance was needed. In its 2010 
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Revision, ARIA was the first chronic respiratory dis-
ease guideline to adopt the GRADE (Grading of Recom-
mendation, Assessment, Development and Evaluation) 
approach, an advanced evidence evaluation methodology 
[4–7]. A new revision is pending.
ARIA has been disseminated and is implemented in 
over 70 countries around the world [8]. It is now focusing 
on the implementation of emerging technologies for indi-
vidualized and predictive medicine. MASK [MACVIA 
(Contre les Maladies Chroniques pour un Vieillissement 
Actif)-ARIA Sentinel NetworK] uses mobile technology 
to develop care pathways for the management of rhinitis 
and asthma by a multi-disciplinary group and by patients 
themselves [9].
The aim of the novel ARIA approach is to provide an 
active and healthy life to rhinitis sufferers, whatever their 
age, sex or socio-economic status in order to reduce 
health and social inequalities incurred by the disease.
AIRWAYS ICPs: the ARIA 2016 political agenda
In 2012, the European Commission launched the Euro-
pean Innovation Partnership on Active and Healthy 
Ageing (EIP on AHA; DG Santé and DG CONNECT) 
to enhance EU competitiveness and tackle societal chal-
lenges through research and innovation [10]. The B3 
Action Plan is devoted to the scaling up and replica-
tion of successful innovative integrated care models for 
chronic diseases amongst older patients.
Chronic respiratory diseases were selected to be the 
pilot for chronic diseases of the EIP on AHA Action Plan 
B3 (Integrated care pathways for airway diseases, AIR-
WAYS ICPs) [11, 12] with a life cycle approach [13]. Sev-
eral effective plans exist in Europe for chronic respiratory 
diseases, but they are rarely deployed to other regions or 
countries.
AIRWAYS ICPs aims to launch a collaboration to 
develop practical multi-sectoral care pathways (i.e. ICPs) 
in European countries and regions to reduce chronic res-
piratory disease burden, mortality and multi-morbidity, 
while maintaining patients’ quality-of-life (QOL) [11, 14]. 
AIRWAYS-ICPs proposes a feasible, achievable and man-
ageable project (from science to guidelines and policies) 
using existing networks. It brings together key stakehold-
ers including end users, public authorities, industry part-
ners, involved in the innovation cycle, from research to 
adoption, as well as those engaged in standardisation and 
regulation. The Action Plan of AIRWAYS ICPs has been 
devised [11], implemented [14] and scaled up [15].
AIRWAYS ICPs is a GARD (WHO Global Alliance 
against Chronic Respiratory Diseases) [16] research dem-
onstration project. Its deployment beyond Europe is car-
ried out via GARD.
One AIRWAYS-ICPs activity is the development of 
multi-sectoral care pathways for rhinitis and asthma and 
their multi-morbidities, implementing emerging technol-
ogies for predictive medicine across the patient life cycle 
[13].
From guidelines to integrated care pathways: 
MACVIA‑ARIA Sentinel NetworK (MASK)
Best practice, guideline and care pathways
A good or best practice is a technique, method, process, 
activity, incentive, or reward believed to be more effective 
than any other technique, method, process, etc. when 
applied to a particular condition or circumstance. A best 
practice can be adopted as a standard process or be used 
as a guideline (U.S. Dept. of Veterans Affairs [17]).
A guideline is a statement to determine a course of 
action. It aims to streamline particular processes accord-
ing to a set routine or sound practice. By definition, fol-
lowing a guideline is never mandatory. Guidelines are 
not binding and are not enforced (U.S. Dept. of Veterans 
Affairs [17]).
“Clinical practice guidelines are systematically devel-
oped statements to assist practitioner and patient deci-
sions about appropriate health care for specific clinical 
circumstances” (Institute of Medicine, 1990). These clini-
cal practice guidelines define the role of specific diag-
nostic and treatment modalities. The statements include 
recommendations based on evidence intended to help 
HCPs and providers in their practice [18].
The Integrated Care Pathway (ICP) concept was initi-
ated in 1985 by Zander and Bower [19]. ICPs are struc-
tured multi-disciplinary care plans detailing key steps of 
patient care for a given clinical problem [20]. They pro-
mote the translation of guidelines into local protocols 
and their subsequent application to clinical practice. An 
ICP forms all or part of the clinical record, documents 
the care given, and facilitates the evaluation of out-
comes for continuous quality improvement [21]. They 
can help empower patients and their carers (health and 
social). ICPs differ from clinical practice guidelines as 
they are utilized by a multi-disciplinary team, and focus 
on the quality and co-ordination of care. ICPs need to 
have a mechanism for recording variations/deviations 
from planned care. Like guidelines, an ICP is a guide to 
treatment, and clinicians are free to exercise their own 
professional judgment as appropriate. However, any 
alteration to the practice identified within this ICP must 
be noted as a variance [22]. Variance analysis is a criti-
cal part of developing and using ICPs [23]. The resulting 
analysis can be used to amend the ICP itself if, for the 
majority of patients, the practice is different to the path-
way (Table 1).
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Multisectoral care pathways for rhinitis and asthma using 
ICT
A large number of AR patients do not consult physi-
cians because they think their AR symptoms are ‘normal’ 
and/or trivial. However, AR negatively impacts social 
life, school and work productivity [3]. Many AR patients 
use over the counter (OTC) drugs [24] and only a frac-
tion have had a medical consultation. The vast majority 
of patients who visit GPs or specialists have moderate/
severe rhinitis [25–29]. Thus, ICPs should consider a 
multi-disciplinary approach as proposed by AIRWAYS 
ICPs (Fig. 1).
The variations/deviations of the ARIA recommenda-
tions from planned care have been assessed and several 
unmet needs identified. Disease severity is associated 
with several health outcomes, including quality of life 
[25–29], and should be considered in ICPs. The dura-
tion of rhinitis (intermittent/severe-persistent) is an 
important indicator of asthma multi-morbidity (in some 
but not all studies) [30], duration of AR treatment and 
efficacy of treatment in AR [27]. Most patients receive 
combinations of oral antihistamines and intra-nasal cor-
ticosteroids (INS) [31–33] which are not evaluated in 
guidelines using an appropriate methodology.
Simple approach to assess control in allergic rhinitis
In asthma, the management strategy is based on disease 
control, current treatment and future risk (exacerbations, 
lung function decline) [34–36]. In AR, the switch from 
symptom severity to disease control to guide treatment 
decisions has been led by ARIA and is now expanding to 
include MACVIA (a reference site of the EIP on AHA, 
EU [37]) to form an Action Plan (MACVIA-ARIA). New 
developments which have facilitated this process include 
(1) the introduction of the visual analogue scale (VAS) as 
the common validated language of AR control, (2) cat-
egorization of AR control using VAS score cut-offs, (3) 
incorporation of this VAS into simple interactive apps 
for both patients (ARIA Allergy Diary) and HCPs (ARIA 
Allergy Diary Companion) [9, 38] and (4) the integration 
of all this knowledge into ICPs deployed by the EIP on 
AHA [9].
The VAS represents a simple way of measuring con-
trol. It has been used in many diseases, including AR. 
VAS scores appear to be similar in different countries, for 
patients with moderate–severe intermittent or persistent 
rhinitis [39, 40]. An advantage of the VAS is that it can 
be used in all age groups, including preschool children 
(guardian evaluation) [41] and the elderly [42, 43]. Fur-
thermore, it can be used in a wide variety of languages 
[39, 40, 42, 44–48]. VAS scores vary with ARIA AR clas-
sification in many languages [28, 44, 49, 50]. A VAS score 
of 50/100  mm suggests moderate–severe AR [32, 51, 
52], although in some studies this cut-off was >60  mm 
[45]. The VAS has been used to define severe chronic 
upper airway disease (SCUAD [53]). The minimal clini-
cally important difference (MCID) during treatment was 
found to be 2.3/10 cm in the French population [54] and 
may be generalized to other countries, but future studies 
may refine this cut-off score. VAS score changes appear 
to encompass both symptoms and disease-specific QOL 
[54, 55].
As is the case for asthma, the best control of AR should 
be achieved as early as possible in order to (1) improve 
patient satisfaction and concordance with treatment and 
(2) reduce the AR burden including symptoms, reduced 
QoL, and school and work presenteeism/absenteeism. 
Untreated AR can impair driving ability and put patients 
at risk [56]. The ultimate goal of AR control is to reduce 
the direct and indirect costs incurred by AR [57–60].
The variability in approaches to achieve disease control 
is challenging, and necessitates careful monitoring as well 
as the step up/step down of individualized therapeutic 
regimens over time. However, the challenges of managing 
AR are increased by the fact that patients do not often 
recognise their AR symptoms or confuse them with those 
of asthma or other multimorbidities such as rhinosinusi-
tis [61]. Therefore, it is important for patients, caregivers 
or HCPs to be able to use an AR symptom scoring system 
that is simple to use and rapidly responsive to change.
The aim is to encourage effective cross communica-
tion and achieve rapid and sustained disease control. 
MACVIA-ARIA has produced a simple VAS-based algo-
rithm called the ARIA Clinical Decision Support System 
(CDSS) using a VAS score to guide treatment decisions 
in a step-up/step-down approach. This CDSS provides 
an individualized approach to AR pharmacotherapy 
(depending on medication availability and resources) 
[62]. This approach holds the potential for optimal AR 
control while minimizing side effects and costs.
MASK (MACVIA‑ARIA Sentinel NetworK): rhinitis 
and asthma
MASK-rhinitis and asthma is a simple ICT tool used to 
implement ICPs for AR and asthma by means of a com-
mon language (for patients and HCPs) and a CDSS. 
Disease control is assessed by VAS, incorporated into 
apps for patients (ARIA Allergy Diary) and HCPs (ARIA 
Allergy Diary Companion), with the utility to assess 
patient QoL (weekly EQ-5D) [63, 64] and school/work 
productivity (weekly WPAI-AS and daily VAS) [25, 65, 
66].
MASK-rhinitis and asthma will (1) allow patients and 
caregivers to screen for AR and asthma, and track their 
AR control (2) guide pharmacists in the prescription of 
OTC medications and referral of patients to physicians 
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when appropriate, (3) allow primary care physicians to 
prescribe appropriate AR treatment, assess patients’ AR 
control and direct follow-ups in accordance with the 
CDSS and (4) encourage referral to specialists and out-
patient clinics, if there is failure to gain AR control at the 
primary care level.
MASK-rhinitis and asthma will be important for estab-
lishing care pathways across the life cycle. It will stratify 
patients with severe uncontrolled disease and achieve 
better results in prevention and intervention trials guided 
by the use of an individualised and predictive medicine 
approach.
The MASK tools: the ARIA Allergy Diary and ARIA Allergy 
Diary Companion apps
The ARIA Allergy Diary is freely available in 15 EU 
countries, Australia, Mexico and Switzerland and in 15 
languages (translated and back-translated, culturally 
adapted and legally compliant). It will also be deployed in 
Brazil, Canada and the USA. The companion app will be 
available in Autumn 2016.
A pilot study was completed in AR during the pol-
len season to assess the relevance of the ARIA Allergy 
Diary app. It showed the importance of the tool to strat-
ify patients, assess their work productivity and improve 
quality of life (EQ-5D) (Bousquet et al., submitted). Stud-
ies in asthma are planned for the autumn and winter.
Questionnaires
ARIA Allergy Diary users fill in simple questionnaires 
on asthma, rhinitis and the impact of the disease (glob-
ally, on work and school, on daily activities and on sleep) 
upon registration (Table  2). The pilot study in around 
5000 users (9% over 60 years of age) indicates that these 
questions are easily answered and can help to stratify 
patients with rhinitis.
Moreover, two specific questionnaires are applied every 
week to assess disease impact on patients’ QoL (EQ-5D) 
[63, 64] and productivity at work (WPAI-AS) [25, 65, 66].
Treatments received
A list of all treatments available for asthma, conjuncti-
vitis and rhinitis is included in the ARIA Allergy Diary, 
and users select the treatment(s) they are taking. Multi-
ple treatments may be selected, and users can update the 
information when (or if ) their treatment changes (Fig. 2). 
The list has been customized for all 20 countries in which 
the ARIA Allergy Diary is available, using data from IMS 
Health. Information on allergen specific immunotherapy 
is also requested on the day of first use. A questionnaire 
on biologics for asthma is under development.
Daily visual analogue scales
Geolocalized users assess their daily symptom control 
using the touchscreen functionality on their smart phone 
to click on 5 consecutive VASs (global symptoms due to 
allergic diseases, rhinitis, conjunctivitis, asthma and work 
productivity) (Fig.  3). These scales have been validated 
for AR and asthma criteria [67–71] and for work produc-
tivity (Bousquet et al., in preparation).
MASK‑asthma
Besides the asthma VAS, a test to measure pulmonary 
function is being developed. It is expected to be added to 
the ARIA Allergy Diary by the end of 2016.
Clinical decision support system
The MASK CDSS is incorporated into an app for HCPs 
(i.e. ARIA Allergy Diary Companion). This is essentially 
an algorithm to aid clinicians to select pharmacotherapy 
for patients with AR and to stratify their disease sever-
ity [62]. It uses a simple step-up/step-down individual-
ized approach to AR pharmacotherapy and may hold 
the potential for optimal control of symptoms, while 
minimizing side effects and costs. However, its use varies 
depending on the availability of medications in the dif-
ferent countries and on resources. A CDSS for asthma is 
also being developed.
Ethics
The terms of use have been translated into all languages 
and customized according to the country’s legislation. 
They allow the use of anonymous data for research and 
commercial purposes. The app has a CE registration as a 
medical device class 1.
Patient empowerment
The validation of the ARIA Allergy Diary has already 
been accomplished (manuscript in preparation). With 
Fig. 1 Multi‑sectoral care pathway for allergic rhinitis (from Bousquet 
et al. [9])
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the help of patient organisations (EFA: European Federa-
tion of Allergy and Airways Diseases Patients’ Associa-
tions), it will be evaluated and improved by the patients 
themselves.
New concepts in allergic multimorbidity embedded 
in ARIA
The term allergic multimorbidity is more appropriate 
than comorbidity since the primary allergic disease is 
poorly known [72].
Stratification of severe allergic and/or asthma patients
Despite the major advances in understanding aller-
gic diseases or asthma, treatments are not effective in 
all patients. From a clinical perspective, implementing 
knowledge-based decisions on what therapeutics to use 
for which patients and, if relevant, in which combina-
tions, is extremely challenging. The aspiration to pro-
vide more effective therapeutic interventions tailored 
to the individual remains unfulfilled because of the 
variable response of individuals to such interventions. 
Patient stratification aims at grouping patients into dis-
ease sub-groups, where the specific pathological pro-
cesses involved are better defined (clinical/molecular 
phenotypes).
Long-term birth cohort studies are essential for under-
standing the life course, early predictors, risk and pro-
tective factors of allergic diseases (including asthma and 
rhinitis) and the complex interplay between genes and 
environment (including life style and socio-economic 
determinants) [73]. MeDALL (Mechanisms of the Devel-
opment of ALLergy; EU FP7-CP-IP; Project No.: 261357; 
2010–2015) attempted to better understand the complex 
links of allergic diseases at the clinical and mechanistic 
levels [74–76].
MeDALL identified a rare but severe allergy phenotype: 
polysensitized-multimorbid phenotype. Although mul-
timorbidity is not always associated with allergy, stud-
ies in MeDALL [77] on children, in the PARIS cohort at 
2 years of age [78], in EGEA on adults [79, 80] (Siroux, in 
preparation) and patient cohorts in subjects with peanut 
allergy [81] all show that subjects who are polysensitized 
and multimorbid have a very high frequency of allergic 
symptoms, persistent symptoms over time, more severe 
asthma symptoms than other phenotypes and higher 
total and specific IgE levels.
Taken altogether, these results indicate that asthmatic 
patients cannot be managed appropriately without 
assessing rhinitis multimorbidity and also reinforce the 
importance of nasal problems (rhinitis and/or rhinosi-
nusitis) in many uncontrolled asthmatic patients [82–84].
Allergic multimorbidity in old age adults
Asthma and rhinitis often start in early age and persist in 
most, but not all, subjects. The expected epidemic wave 
of asthma and rhinitis in older adults is an insufficiently 
recognized problem. In Europe, over 20% of adults suf-
fer from AR and over 5% from asthma. These patients 
are now reaching the age of 65  years and a new health 
problem in older adults will be to understand, detect 
and manage these patients. Asthma and rhinitis in older 
adults have specific symptoms and treatment needs, 
which are different from those in younger adults. These 
patients also suffer from multi-morbididy with high rates 
of poly-pharmacy reported. Integrated Care Pathways 
(ICPs) for rhinitis and asthma should cover the entire life 
cycle.
Table 2 Baseline questionnaire
Q1: I have rhinitis: yes/no
Q2: I have asthma: yes/no
Q3: My symptoms (tick)
 Runny nose
 Itchy nose
 Sneezing
 Congestion (blocked nose)
 Red eyes
 Itchy eyes
 Watery eyes
Q4: How they affect me: my symptoms (tick)
 Affect my sleep
 Restrict my daily activities
 Restrict my participation in school or work
 Are troublesome
Q5: Medications
Q6: Are you currently receiving immunotherapy (a small dose of the 
thing you are allergic to, usually taken as an injection or placed under 
your tongue)? yes/no
 If YES to Q6 (Q7 and Q8)
Q7: What allergy is this?
 Grass pollen
 Parietaria pollen
 Birch pollen
 Other pollen
 Dust mite
 Animal
 Cypress tree pollen
 Don’t know
 Add allergy
Q8: How do you receive your treatment?
 Injection
 Tablet under the tongue
 Drops under the tongue
 Spray under the tongue
 Other
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The scaling up strategy
The EIP on AHA has proposed a 5-step framework for 
developing an individual scaling up strategy: (1) what to 
scale up: (1-a) databases of good practices, (1-b) assess-
ment of viability of the scaling up of good practices, (1-c) 
classification of good practices for local replication and 
(2) how to scale up: (2-a) facilitating partnerships for 
scaling up, (2-b) implementation of key success factors 
and lessons learnt, including emerging technologies for 
individualised and predictive medicine. This strategy has 
Fig. 2 Screens on medications
Fig. 3 Screens on daily visual analogue scales
Page 9 of 14Bousquet et al. Clin Transl Allergy  (2016) 6:47 
already been applied to the chronic respiratory diseases 
action plan of the EIP on AHA [15].
There is an urgent need for scaling up strategies in 
order to (1) avoid fragmentation, (2) improve health care 
delivery across Europe, (3) speed up the implementation 
of good practices using existing cost-effective success sto-
ries and (4) meet the EIP on AHA objectives [10].
Reference Site Collaborate Network (RSCN) of the EIP 
on AHA
The RSCN brings together all EIP on AHA Reference 
Sites, and Candidate Reference Sites, across Europe into 
a single forum. The aim is to promote cooperation and 
develop and promote areas of innovative good prac-
tice and solutions, which contribute to improved health 
and care outcomes for citizens across Europe. The hope 
is to develop sustainable economic growth and create 
jobs. Members of 13 EIP on AHA Reference Sites (2013) 
have agreed on the AIRWAYS ICPs concept and are co-
authors of the paper published in Clinical Translational 
Allergy [15]. A meeting of all EIP on AHA Reference 
Sites was co-organised by the Région LR, North Eng-
land [85] and the EIP on AHA Reference Site Collabora-
tive Network to scale up AIRWAYS ICPs in all Reference 
Sites (October 21, 2014). 74 EIP on AHA Reference Sites 
have now been approved by the EU (2016). A Twinning 
project has also been approved by the EIP on AHA to 
deploy MASK in 13 Reference Sites in order to compare 
allergic rhinitis diagnoses by allergists in adults and older 
people to study phenotypes, treatments and care path-
ways of rhinitis.
Conclusion
 ARIA has evolved from a rigorously developed guideline 
to a mobile technology-based implementation strategy 
in order to provide an active and healthy life to rhinitis 
sufferers, whatever their age, sex or socio-economic sta-
tus with the aim to reduce health and social inequalities 
incurred by this very common disease globally.
Abbreviations
AIRWAYS ICPs: integrated care pathways for airway diseases; AR: allergic 
rhinitis; ARIA: Allergic Rhinitis and its Impact on Asthma; CDSS: Clinical Deci‑
sion Support System; COPD: chronic obstructive pulmonary disease; DG: 
Directorate General; EAACI: European Academy of Allergy and Clinical Immu‑
nology; EIP on AHA: European Innovation Partnership on Active and Healthy 
Ageing; EU: European Union; FP: Framework Programme (EU); GA2LEN: Global 
Allergy and Asthma European Network (FP6); GARD: WHO Global Alliance 
against Chronic Respiratory Diseases; GRADE: Grading of Recommendation, 
Assessment, Development and Evaluation; HCP: health care professional; ICP: 
integrated care pathway; IPCRG: International Primary Care Respiratory Group; 
MACVIA‑LR: Contre les Maladies Chroniques pour un Vieillissement Actif (fight‑
ing chronic diseases for active and healthy ageing); MASK: MACVIA‑ARIA Sen‑
tinel NetworK; MeDALL: Mechanisms of the Development of ALLergy (EU FP7); 
MOH: Ministry of Health; NCD: non‑communicable disease; NHS: National 
Health Service; RCT: randomized controlled trial; RQLQ: Rhinoconjunctivitis 
Quality of Life Questionnaire; RSCN: Reference Site Collaborative Network; 
SCUAD: severe chronic upper airway disease; VAS: visual analogue scale; WHO: 
World Health Organization.
Authors’ contributions
All authors are participating to the ARIA and AIRWAYS ICPs projects globally. 
All authors participated in «ARIA 2016: Care pathways implementing emerg‑
ing technologies for predictive medicine in rhinitis and asthma across the life 
cycle» . All authors read and approved the final manuscript.
Author details
1 Montpellier University Hospital, Montpellier, France. 2 MACVIA‑France, Contre 
les MAladies Chroniques pour un VIeillissement Actif en France, European 
Innovation Partnership on Active and Healthy Ageing Reference Site, 
Montpellier, France. 3 INSERM, U1168, Ageing and Chronic Diseases 
Epidemiological and Public Health Approaches, 94800 Villejuif, France. 
4 Laboratory of Clinical Immunology, Department of Microbiology and Immu‑
nology, KU Leuven, Louvain, Belgium. 5 Transylvania University Brasov, Brasov, 
Romania. 6 Upper Airways Research Laboratory, ENT Department, Ghent 
University Hospital, Ghent, Belgium. 7 Allergy‑Centre‑Charité, Department 
of Dermatology and Allergy, Charité ‑ Universitätsmedizin Berlin, Berlin, 
Germany. 8 Global Allergy and Asthma European Network (GA²LEN), Berlin, 
Germany. 9 iQ4U Consultants Ltd, London, UK. 10 Department of Dermatology 
and Allergy Centre, Odense University Hospital, Odense, Denmark. 11 Wool‑
cock Institute of Medical Research, University of Sydney and Sydney Local 
Health District, Glebe, NSW, Australia. 12 University Pneumology Unit‑AOU 
Molinette, Hospital City of Health and Science of Torino, Turin, Italy. 
13 Department of Respiratory Diseases, Montpellier University Hospital, 
Montpellier, France. 14 Department of Pediatrics, Medical School, Federal 
University of Minas Gerais, Belo Horizonte, Brazil. 15 Asthma and Allergy Clinic, 
Humanitas University, Rozzano, Milan, Italy. 16 Division of Allergy/Immunology, 
University of South Florida, Tampa, FL, USA. 17 Department of Public Health 
and Primary Care, Leiden University Medical Center, Leiden, The Netherlands. 
18 ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, 
Salvador, Brazil. 19 GARD Executive Committee, Salvador, Bahia, Brazil. 20 EFA 
European Federation of Allergy and Airways Diseases Patients’ Associations, 
Brussels, Belgium. 21 EPAR U707 INSERM, Paris, France. 22 EPAR UMR‑S UPMC, 
Paris VI, Paris, France. 23 Laboratoire de Pharmacologie Respiratoire UPRES 
EA220, Hôpital Foch, Suresnes Université Versailles, Saint‑Quentin, France. 
24 Center for Research in Health Technologies and Information Systems 
‑ CINTESIS, Universidade do Porto, Porto, Portugal. 25 Allergy Unit, Instituto CUF 
Porto e Hospital CUF Porto, Porto, Portugal. 26 Health Information and Decision 
Sciences Department ‑ CIDES, Faculdade de Medicina, Universidade do Porto, 
Rua Dr. Plácido da Costa, s/n, 4200‑450 Porto, Portugal. 27 Department 
of Otorhinolaryngology, Academic Medical Centre, Amsterdam, The 
Netherlands. 28 Institute of Health Policy and Management IBMG, Erasmus 
University, Rotterdam, The Netherlands. 29 Skin and Allergy Hospital, Helsinki 
University Hospital, Helsinki, Finland. 30 Federico II University Hospital Naples 
(R&D and DISMET), Naples, Italy. 31 Allergology Department, Centre de 
l’Asthme et des Allergies, Hôpital d’Enfants Armand‑Trousseau (APHP), 
Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis 
d’Epidémiologie et de Santé Publique, Equipe EPAR, 75013 Paris, France. 
32 Institute of Social Medicine, Epidemiology and Health Economics, Charité 
‑ Universitätsmedizin Berlin, Berlin, Germany. 33 Institute for Clinical 
Epidemiology and Biometry, University of Wuerzburg, Würzburg, Germany. 
34 Center for Rhinology and Allergology, Wiesbaden, Germany. 35 Division 
of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical 
University of Lodz, Lodz, Poland. 36 Clínica de Alergia, Asma y Pediatría, 
Hospital Médica Sur, Mexico City, Mexico. 37 Allergy and Clinical Immunology 
Department, Hospital CUF‑Descobertas, Lisbon, Portugal. 38 ENT Department, 
Hospital Clinic, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, 
CIBERES, Universitat de Barcelona, Barcelona, Catalonia, Spain. 39 MedScript 
Ltd, Dundalk, County Louth, Ireland. 40 Section of Otolaryngology‑Head 
and Neck Surgery, The University of Chicago Medical Center and The Pritzker 
School of Medicine, The University of Chicago, Chicago, IL, USA. 41 Department 
of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central 
Clinical School, Monash University, Melbourne, VIC, Australia. 42 Department 
of Immunology, Monash University, Melbourne, VIC, Australia. 43 Center 
for Pediatrics and Child Health, Institute of Human Development, Royal 
Manchester Children’s Hospital, University of Manchester, Manchester, UK. 
Page 10 of 14Bousquet et al. Clin Transl Allergy  (2016) 6:47 
44 Allergy Department, 2nd Pediatric Clinic, Athens General Children’s Hospital 
“P&A Kyriakou”, University of Athens, Athens, Greece. 45 Department 
of Pediatrics, Nippon Medical School, Tokyo, Japan. 46 Allergy Diagnostic 
and Clinical Research Unit, University of Cape Town Lung Institute, Cape Town, 
South Africa. 47 Woodbrook Medical Centre, Loughborough, UK. 48 Allergy 
and Respiratory Research Group, The University of Edinburgh, Edinburgh, UK. 
49 Department of Prevention of Environmental Hazards and Allergology, 
Medical University of Warsaw, Warsaw, Poland. 50 Department of Clinical 
Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada. 
51 Allergy and Respiratory Research Group, Centre for Population Health 
Sciences, The University of Edinburgh Medical School, Edinburgh, UK. 
52 Department of Pediatrics and Child Health, Department of Immunology, 
Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada. 53 Division 
of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy. 
54 Centre of Pneumology, Faculty of Medicine, University of Coimbra, Coimbra, 
Portugal. 55 Department of ENT, Medical University of Graz, Graz, Austria. 
56 Clinic of Children’s Diseases, Faculty of Medicine, Vilnius University, Vilnius, 
Lithuania. 57 Public Health Institute, Vilnius University, Vilnius, Lithuania. 
58 European Academy of Paediatrics (EAP/UEMS‑SP), Brussels, Belgium. 
59 Department of Lung Diseases and Clinical Allergology, University of Turku, 
Turku, Finland. 60 Allergy Clinic, Terveystalo, Turku, Finland. 61 Unit of Geriatric 
Immunoallergology, University of Bari Medical School, Bari, Italy. 62 Sachs’ 
Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden. 63 Institute 
of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 
64 Queen’s University, Belfast, Northern Ireland, UK. 65 Department of Pulmo‑
nology, Celal Bayar University, Manisa, Turkey. 66 Department of Dermatology, 
Medical University of Graz, Graz, Austria. 67 Swiss Institute of Allergy 
and Asthma Research (SIAF), University of Zurich, Davos, Switzerland. 
68 Department of Allergy and Immunology, Hospital Quirón Bizkaia, Erandio, 
Spain. 69 Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain. 
70 IMIM (Hospital del Mar Research Institute), Barcelona, Spain. 71 CIBER 
Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. 72 Universitat 
Pompeu Fabra (UPF), Barcelona, Spain. 73 Kyomed, Montpellier, France. 
74 Clinical Immunology and Allergy Unit, Department of Medicine Solna, 
Karolinska Institutet, Stockholm, Sweden. 75 Department of Pediatric 
Pulmonology and Allergy, Astrid Lindgren Children’s Hospital, Karolinska 
University Hospital, Stockholm, Sweden. 76 David Hide Asthma and Allergy 
Research Centre, Isle of Wight, UK. 77 Regionie Puglia, Bari, Italy. 78 Faculdade 
de Medicina de Lisboa, Portuguese National Programme for Respiratory 
Diseases (PNDR), Lisbon, Portugal. 79 Geriatric Unit, Department of Internal 
Medicine (DIBIMIS), University of Palermo, Palermo, Italy. 80 Department 
of Medicine, University of Cape Town, Cape Town, South Africa. 81 Section 
of Respiratory Disease, Department of Oncology, Haematology and Respira‑
tory Diseases, University of Modena and Reggio Emilia, Modena, Italy. 
82 Department of Respiratory Medicine, Academic Medical Center (AMC), 
University of Amsterdam, Amsterdam, The Netherlands. 83 Department 
of Respiratory Medicine, National Institute of Diseases of the Chest and Hospi‑
tal, Dhaka, Bangladesh. 84 Centre for Individualized Medicine, Department 
of Pediatrics, Faculty of Medicine, Linköping University, 58185 Linköping, 
Sweden. 85 Department of Dermatology and Allergy, Rheinische Friedrich‑
Wilhelms‑University Bonn, Bonn, Germany. 86 Department of Respiratory 
Medicine and Allergology, University Hospital, Lund, Sweden. 87 Department 
of Geriatrics, Montpellier University Hospital, Montpellier, France. 88 EA 2991, 
Euromov, University Montpellier, Montpellier, France. 89 Department 
of Pathophysiology and Transplantation, IRCCS Fondazione Ca’Granda 
Ospedale Maggiore Policlinico, University of Milan, Milan, Italy. 90 Pediatric 
Department, University of Verona Hospital, Verona, Italy. 91 Department 
of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, 
Italy. 92 Second University of Naples and Institute of Translational Medicine, 
Italian National Research Council, Naples, Italy. 93 La Rochelle, France. 
94 Montreal, QC, Canada. 95 Quebec Heart and Lung Institute, Laval University, 
Quebec City, QC, Canada. 96 Health Economics and Health Technology 
Assessment, Institute of Health and Wellbeing, University of Glasgow, Glasgow, 
UK. 97 Institute of Lung Health, Respiratory Biomedical Unit, University 
Hospitals of Leicester NHS Trust, Leicestershire, UK. 98 Department of Infection, 
Immunity and Inflammation, University of Leicester, Leicester, UK. 99 Univer‑
sitätsmedizin der Johannes Gutenberg‑Universität Mainz, Mainz, Germany. 
100 University of Medicine and Pharmacy Victor Babes, Timisoara, Romania. 
101 Royal Brompton Hospital NHS, Imperial College London, London, UK. 
102 Centro Medico Docente La Trinidad, Caracas, Venezuela. 103 National Heart 
and Lung Institute, Imperial College London, London, UK. 104 Montpellier, 
Région Languedoc Roussillon, France. 105 S. Allergologia, S. Medicina Interna, 
Hospital Vall d’Hebron, Barcelona, Spain. 106 CEDOC, Respiratory Research 
Group, Nova Medical School, Campo dos Martires da Patria, Lisbon, Portugal. 
107 Serviço de Imunoalergologia, Centro Hospitalar de Lisboa Central, EPE, 
Lisbon, Portugal. 108 Regional Ministry of Health of Andalusia, Seville, Spain. 
109 Department of Paediatrics, Oslo University Hospital, Oslo, Norway. 
110 University of Oslo, Oslo, Norway. 111 Allergy and Asthma Associates 
of Southern California, Mission Viejo, CA, USA. 112 Allergy and Immunology 
Laboratory, Metropolitan University, Simon Bolivar University, Barranquilla, 
Colombia. 113 SLaai, Sociedad Latinoamericana de Allergia, Asma e Immunolo‑
gia, Cartagena, Colombia. 114 Gérontopôle de Toulouse, 31059 Toulouse, 
France. 115 Department of Social Medicine, Faculty of Medicine, University 
of Crete, Heraklion, Crete, Greece. 116 School of Medicine, University CEU San 
Pablo, Madrid, Spain. 117 Chachava Clinic, David Tvildiani Medical Univer‑
sity‑AIETI Medical School, Grigol Robakidze University, Tbilisi, Georgia. 
118 Pulmonolory Research Institute FMBA, Moscow, Russia. 119 GARD Executive 
Committee, Moscow, Russia. 120 Medicine Department, IRCCS‑Azienda 
Ospedaliera Universitaria San Martino, Genoa, Italy. 121 ICVS/3B’s‑PT 
Government Associate Laboratory, Life and Health Sciences, Research Institute 
(ICVS), School of Health Sciences, University of Minho, Braga, Portugal. 
122 Department of Medicine, Nova Southeastern University, Davie, FL, USA. 
123 EIP on AHA, European Innovation Partnership on Active and Healthy 
Ageing, Reference Site, Scottish Centre for Telehealth and Telecare, NHS 24, 
Glasgow, UK. 124 Department of Pediatric, Imperial College London, London, 
UK. 125 The Centre for Allergy Research, The Institute of Environmental 
Medicine, Karolinska Institutet, Stockholm, Sweden. 126 Department 
of Dermatology and Allergy, Technische Universität München, Munich, 
Germany. 127 ZAUM‑Center for Allergy and Environment, Helmholtz Center 
Munich, Munich, Germany. 128 AQuAS, Barcelona, Spain. 129 EUREGHA, 
European Regional and Local Health Association, Brussels, Belgium. 
130 Allergology and Immunology Discipline, “Luliu Hatieganu” University 
of Medicine and Pharmacy, Cluj‑Napoca, Romania. 131 Division of Clinical 
Immunology and Allergy, Department of Medicine, McMaster University, 
Hamilton, ON, Canada. 132 Peercode DV, Amsterdam, The Netherlands. 
133 Respiratory Diseases Department, Rangueil‑Larrey Hospital, Toulouse, 
France. 134 Service de Physiologie Respiratoire, Hôpital Cochin, Université 
Paris‑Descartes, Assistance Publique‑Hôpitaux de Paris, Paris, France. 
135 University Clinic of Pulmology and Allergy, Medical Faculty, Ss Cyril 
and Methodius University, Skopje, Republic of Macedonia. 136 Service de 
Pneumo‑Allergologie, Centre Hospitalo‑Universitaire de Béni‑Messous, Algers, 
Algeria. 137 Ecole des Mines, Alès, France. 138 Medical Faculty, Vilnius University, 
Vilnius, Lithuania. 139 Allergy and Clinical Immunology Section, National Heart 
and Lung Institute, Imperial College London, London, UK. 140 Guy’s and St 
Thomas’ NHS Trust, Kings College London, London, UK. 141 Section of Allergy 
and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, 
USA. 142 Computing Science Department, Umeå University, Umeå, Sweden. 
143 Four Computing Oy, Halikko, Finland. 144 Pediatric Allergy and Immunology 
Unit, Ain Shams University, Cairo, Egypt. 145 Department of Health, Social 
Services and Public Safety, Belfast, Northern Ireland, UK. 146 Global Allergy 
and Asthma Platform GAAPP, Altgasse 8‑10, 1130 Vienna, Austria. 147 Division 
of Allergy, Department of Pediatric Medicine, The Bambino Gesù Children’s 
Research Hospital Holy See, Rome, Italy. 148 Education for Health, Warwick, UK. 
149 Department of Epidemiology, Regional Health Service Lazio Region, Rome, 
Italy. 150 Athens Chest Hospital, Athens, Greece. 151 National Center for Disease 
Control and Public Health of Georgia, Tbilisi, Georgia. 152 Department 
of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University, 
Istanbul, Turkey. 153 Allergy and Immunology Division, Clinica Ricardo Palma, 
Lima, Peru. 154 Section of Allergology, Department of Internal Medicine, 
Erasmus MC, Rotterdam, The Netherlands. 155 Universidad Autónoma de 
Nuevo León, San Nicolás de los Garza, Mexico. 156 Center of Tuberculosis 
and Lung Diseases, Latvian Association of Allergists, Riga, Latvia. 157 Faculty 
of the Department of Neurology, University of Washington School of Medi‑
cine, Seattle, WA, USA. 158 National eHealth Centre, University Hospital 
Olomouc, Olomouc, Czech Republic. 159 Immunology and Allergy Division 
Clinical Hospital, University of Chile, Santiago, Chile. 160 Department 
of Respiratory Diseases, Odense University Hospital, Odense, Denmark. 
161 Institute of Epidemiology I, Helmholtz Zentrum München ‑ German 
Research Center for Environmental Health, Neuherberg, Germany. 162 Vienna 
Challenge Chamber, Vienna, Austria. 163 Department of Paediatrics and Child 
Health, University College Cork, Cork, Ireland. 164 Université Paris‑Sud, Le 
Kremlin Bicêtre, France. 165 Service de Pneumologie, Hôpital Bicêtre, Le Kremlin 
Page 11 of 14Bousquet et al. Clin Transl Allergy  (2016) 6:47 
Bicêtre, France. 166 Inserm UMR_S999, Le Kremlin Bicêtre, France. 167 School 
of Psychology, Plymouth University, Plymouth, UK. 168 Department of Medicine 
and Surgery, University of Salerno, Baronissi, Italy. 169 Libra Foundation, Buenos 
Aires, Argentina. 170 Airway Disease Infection Section, National Heart and Lung 
Institute, Imperial College London, London, UK. 171 MRC & Asthma UK Centre 
in Allergic Mechanisms of Asthma, London, UK. 172 Department of Respiratory 
Medicine, Ghent University Hospital, Ghent, Belgium. 173 Medical Commission, 
Montpellier University Hospital, Montpellier, France. 174 Hallym University 
Sacred Heart Hospital, Hallym University College of Medicine, Anyang, 
Gyeonggi‑do, South Korea. 175 Department of Clinical Immunology, Wrocław 
Medical University, Wrocław, Poland. 176 Ukrainian Medical Stomatological 
Academy, Poltava, Ukraine. 177 Laboratory of Molecular Immunology, National 
Research Center, Institute of Immunology, Federal Medicobiological Agency, 
Moscow, Russia. 178 Pediatric Allergy and Asthma Unit, School of Medicine, 
Hacettepe University, Ankara, Turkey. 179 Immunology and Allergy Division, 
Department of Chest Diseases, School of Medicine, Hacettepe University, 
Ankara, Turkey. 180 First Department of Family Medicine, Medical University 
of Lodz, Lodz, Poland. 181 Department of Medicine, McMaster University, 
Health Sciences Centre 3V47, 1280 Main Street West, Hamilton, ON, Canada. 
182 Department of Pulmonary Diseases, University Medical Center Groningen, 
University of Groningen, Groningen, The Netherlands. 183 GARD, Geneva, 
Switzerland. 184 Department of Respiratory Medicine, Faculty of Medicine 
and Dentistry, University Hospital Olomouc, Olomouc, Czech Republic. 
185 Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix 
Children’s Hospital, GRIAC Research Institute, University Medical Center 
Groningen, University of Groningen, Groningen, The Netherlands. 186 Depart‑
ment of Immunology, Rheumatology and Allergy and HARC, Medical 
University of Lodz, Lodz, Poland. 187 Children’s Hospital, University of Helsinki, 
Helsinki, Finland. 188 Clinic of Infectious, Chest Diseases, Dermatology 
and Allergology, Vilnius University, Vilnius, Lithuania. 189 VIB Inflammation 
Research Center, Ghent University, Ghent, Belgium. 190 Department 
for Pediatric Pneumology and Immunology, Charité Medical University, Berlin, 
Germany. 191 University of Medicine and Pharmacy, Hochiminh City, Vietnam. 
192 Divisions of Allergy and Immunology, Department of Internal Medicine 
and Pediatrics, University of Tennessee College of Medicine, Germantown, TN, 
USA. 193 Scottish Centre for Respiratory Research, Cardiovascular and Diabetes 
Medicine, Medical Research Institute, Ninewells Hospital, University of Dundee, 
Dundee, UK. 194 State Key Laboratory of Respiratory Diseases, Guangzhou 
Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou 
Medical University, Guangzhou, China. 195 Institute of Clinical Medicine, Faculty 
of Medicine, University of Oslo, Oslo, Norway. 196 Department of Pulmonary 
Medicine, CHU Sart‑Tilman, Liege, Belgium. 197 Division of Immunopathology, 
Department of Pathophysiology and Allergy Research, Center for Pathophysi‑
ology, Infectiology and Immunology, Medical University of Vienna, Vienna, 
Austria. 198 The Queen’s Medical Research Institute, University of Edinburgh, 
Edinburgh, UK. 199 Service de Pneumo‑allergologie, Hôpital Saint‑Joseph, Paris, 
France. 200 Service de Pneumologie, UMR INSERM, UMR1087 and CNR 6291, 
l’institut du Thorax, University of Nantes, Nantes, France. 201 Department 
of Pulmonary Medicine, Rashid Hospital, Dubai, UAE. 202 Biomax Informatics 
AG, Munich, Germany. 203 Department of Respiratory Medicine, University 
of Bratislava, Bratislava, Slovakia. 204 Institute of Biomedical Imaging and Life 
Sciences (IBILI), Faculty of Medicine, University of Coimbra, Coimbra, Portugal. 
205 Ageing@Coimbra EIP‑AHA Reference Site, Coimbra, Portugal. 206 Depart‑
ment of Medicine (RCSI), Bon Secours Hospital, Glasnevin, Dublin, Ireland. 
207 Kronikgune, Basque Region, Spain. 208 Laboratory of Behavioral Immunol‑
ogy Research, Division of Clinical Immunology and Allergy, The University 
of Mississippi Medical Center, Jackson, MS, USA. 209 Tobacco Control Research 
Centre, Iranian Anti Tobacco Association, Tehran, Iran. 210 Department 
of Paediatrics, Maputo Central Hospital, Maputo, Mozambique. 211 Allergy 
and Asthma Medical Group and Research Center, San Diego, CA, USA. 
212 Department of Physiology, CHRU, PhyMedExp, INSERM U1046, CNRS UMR 
9214, University Montpellier, Montpellier, France. 213 Hautklinik ‑ Klinik für 
Dermatologie & Allergologie, Universitätsklinikum der RWTH Aachen, Aachen, 
Germany. 214 Croatian Pulmonary Society, Zagreb, Croatia. 215 National Institute 
of Pneumology M. Nasta, Bucharest, Romania. 216 Faculty of Medicine, 
University of Belgrade, Belgrade, Serbia. 217 Serbian Association for Asthma 
and COPD, Belgrade, Serbia. 218 Caisse d’assurance retraite et de la santé au 
travail du Languedoc‑Roussillon (CARSAT‑LR), Montpellier, France. 219 National 
Center for Research in Chronic Respiratory Diseases, Tishreen University School 
of Medicine, Latakia, Syria. 220 Department of Public Health and Health 
Products, EA 4064, Paris Descartes University‑Sorbonne Paris Cité, Paris, France. 
221 Paris Municipal Department of Social Action, Childhood, and Health, Paris, 
France. 222 Institute of Medical Statistics, Informatics and Epidemiology, 
Medical Faculty, University of Cologne, Cologne, Germany. 223 Food Allergy 
Referral Centre Veneto Region, Department of Women and Child Health, 
Padua General University Hospital, Padua, Italy. 224 Scientific Centre of Chil‑
dren’s Health Under the Russian Academy of Medical Sciences, Moscow, 
Russia. 225 Hospital de Niños Orlando Alassia, Santa Fe, Argentina. 226 Hospital 
of the Hospitaller Brothers in Buda, Budapest, Hungary. 227 Neumología y 
Alergología Infantil, Hospital La Fe, Valencia, Spain. 228 Department of Internal 
Medicine, Centro Hospitalar Sao Joao, Porto, Portugal. 229 ENT Department, 
University Hospital of Kinshasa, Kinshasa, Congo. 230 National Hospital 
Organization, Tokyo National Hospital, Tokyo, Japan. 231 Department 
of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan. 232 Depart‑
ment of Otolaryngology, Nippon Medical School, Tokyo, Japan. 233 Centre 
Hospitalier Universitaire Pédiatrique Charles de Gaulle, Ouagadougou, Burkina 
Faso. 234 Cardio‑Thoracic and Vascular Department, University Hospital of Pisa, 
Pisa, Italy. 235 Department of Comparative Medicine, Messerli Research 
Institute of the University of Veterinary Medicine, Medical University, Vienna, 
Austria. 236 Department of Immunology and Allergology, Faculty of Medicine 
and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czech 
Republic. 237 Respiratory Medicine, Department of Medical Sciences, University 
of Ferrara, Ferrara, Italy. 238 Department of Allergy and Clinical Immunology, 
Ajou University School of Medicine, Suwon, South Korea. 239 University 
of Southern Denmark, Kolding, Denmark. 240 Allergy Unit, CUF‑Porto Hospital 
and Institute, Porto, Portugal. 241 Department of Otorhinolaryngology, Head 
and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, 
Heidelberg University, Mannheim, Germany. 242 Conseil Général de 
l’Economie, Ministère de l’Economie, de l’Industrie et du Numérique, Paris, 
France. 243 Société de Pneumologie de Langue Française, Espace francophone 
de Pneumologie, Paris, France. 244 Département de pédiatrie, CHU de 
Grenoble, Grenoble, France. 245 Children’s Hospital Srebrnjak, Zagreb, Croatia. 
246 School of Medicine, University J.J. Strossmayer, Osijek, Croatia. 247 Karl 
Landsteiner Institute for Clinical and Experimental Pneumology, Hietzing 
Hospital, Vienna, Austria. 248 Clinic of Allergy and Asthma, Medical University 
Sofia, Sofia, Bulgaria. 249 University Medical Center Groningen, University 
of Groningen, Groningen, The Netherlands. 250 Laboratory of Medical 
Allergology, Allergy Clinic, Copenhagen University Hospital at Gentofte, 
Copenhagen, Denmark. 251 Academic Centre of Primary Care, University 
of Aberdeen, Aberdeen, Scotland, UK. 252 Research in Real‑Life, Cambridge, UK. 
253 LungenClinic Grosshansdorf, Airway Research Center North, German 
Center for Lung Research (DZL), Grosshansdorf, Germany. 254 Department 
of Medicine, Christian Albrechts University, Airway Research Center North, 
German Center for Lung Research (DZL), Kiel, Germany. 255 NHS Foundation 
Trust, University Hospitals of Southampton, Southampton, UK. 256 Centre 
of Pneumology, Coimbra University Hospital, Coimbra, Portugal. 257 Polibien‑
estar Research Institute, University of Valencia, Valencia, Spain. 258 Department 
of Geriatrics, Getafe University Hospital, Madrid, Spain. 259 Association Asthme 
et Allergie, Paris, France. 260 Primary Care Respiratory Research Unit, Institutode 
Investigación Sanitaria de Palma IdisPa, Palma de Mallorca, Spain. 261 Allergy 
Unit, Complesso Integrato Columbus, Rome, Italy. 262 Serviço de Imunoalerg‑
ologia, Hospital da Luz, Lisbon, Portugal. 263 Hospital de Clinicas, University 
of Parana, Curitiba, Brazil. 264 Division of Allergy Asthma and Clinical 
Immunology, Emek Medical Center, Afula, Israel. 265 Allergy and Clinical 
Immunology Department, Centro Médico‑Docente La Trinidad and Clínica El 
Avila, Caracas, Venezuela. 266 Faculty of Medicine, Autononous University 
of Madrid, Madrid, Spain. 267 The Royal National TNE Hospital, University 
College London, London, UK. 268 DIBIMIS, University of Palermo, Palermo, Italy. 
269 Allergy Unit, Department of Dermatology, University Hospital of Zurich, 
Zurich, Switzerland. 270 Otolaryngology and Head and Neck Surgery, CHU 
Rangueil‑Larrey, Toulouse, France. 271 Child Health, Queen’s University, Belfast, 
Northern Ireland, UK. 272 Royal Belfast Hospital for Sick Children, Belfast, 
Northern Ireland, UK. 273 INSERM, Université Grenoble Alpes, IAB, U 1209, Team 
of Environmental Epidemiology Applied to Reproduction and Respiratory 
Health, Université Joseph Fourier, Grenoble, France. 274 Sociedad Paraguaya de 
Alergia Asma e Inmunologıa, Asunción, Paraguay. 275 Julius Center of Health 
Sciences and Primary Care, University Medical Center Utrecht, University 
of Utrecht, Utrecht, The Netherlands. 276 Division of Allergy, Clinical Immunol‑
ogy and Rheumatology, Department of Pediatrics, Federal University of São 
Paulo, São Paulo, Brazil. 277 Kyrgyzstan National Centre of Cardiology 
and Internal Medicine, Euro‑Asian Respiratory Society, Bishkek, Kyrgyzstan. 
278 Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da 
Page 12 of 14Bousquet et al. Clin Transl Allergy  (2016) 6:47 
Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Brazil. 
279 Academic Medical Centre, University of Amsterdam, Amsterdam, The 
Netherlands. 280 European Union Geriatric Medicine Society (EUGMS), Helsinki, 
Finland. 281 Department of Epidemiology, CAPHRI School of Public Health 
and Primary Care, Maastricht University, Maastricht, The Netherlands. 
282 Pneumology and Allergy Department, Hospital Clínic, Clinical and Experi‑
mental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain. 283 PELyon, 
Lyon, France. 284 HESPER 7425, Health Services and Performance Resarch, 
Université Claude Bernard Lyon, Villeurbanne, France. 285 University Hospital, 
Stockholm, Sweden. 286 Department of Chest Medicine, Centre Hospitalier 
Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium. 
287 Philippines Society of Allergy, Asthma and Immunology, Manila, 
Philippines. 288 Pulmonary Unit, Department of Cardiology, Thoracic 
and Vascular Medicine, Arcispedale S. Maria Nuova/IRCCS, Research Hospital, 
Reggio Emilia, Italy. 289 Regional Agency for Health and Social Care, Reggio 
Emilia, Italy. 290 Finnish Lung Association (FILHA), Helsinki, Finland. 291 Pulmo‑
nary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, 
Pisa, Italy. 292 CNR Institute of Biomedicine and Molecular Immunology “A. 
Monroy”, Palermo, Italy. 293 Sotiria Hospital, Athens, Greece. 294 Department 
of Otorhinolaryngology, HNO‑Klinik, Universitätsklinikum Düsseldorf, 
Düsseldorf, Germany. 295 Asthma UK, Mansell Street, London, UK. 296 Depart‑
ment of Otolaryngology, Yong Loo Lin School of Medicine, National University 
of Singapore, Singapore, Singapore. 297 Division of Immunodermatology 
and Allergy Research, Department of Dermatology and Allergy, Hannover 
Medical School, Hannover, Germany. 298 Eshelman School of Pharmacy, 
University of North Carolina, Chapel Hill, NC, USA. 299 IPCRG, Aberdeen, 
Scotland, UK. 300 Bradford Institute for Health Research, Bradford Royal 
Infirmary, Bradford, UK. 301 Department of Research, Olmsted Medical Center, 
Rochester, MN, USA. 302 Medical School, University of Cyprus, Nicosia, Cyprus. 
303 The Allergy and Asthma Institute, Lahore, Pakistan. 304 Social Sciences, 
University of Southampton, Southampton, UK. 305 Department of Paediatrics 
and Child Health, Red Cross Children’s Hospital, University of Cape Town, Cape 
Town, South Africa. 306 MRC Unit on Child and Adolescent Health, University 
of Cape Town, Cape Town, South Africa. 307 Universidad Católica de Córdoba, 
Córdoba, Argentina. 308 Department of Otolaryngology Head and Neck 
Surgery, Beijing TongRen Hospital, Beijing, China. 309 Beijing Institute 
of Otolaryngology, Beijing, China. 310 University Clinic of Respiratory 
and Allergic Diseases, Golnik, Slovenia. 311 Northern Health Alliance, Newcastle, 
UK. 312 CHRU Arnaud de Villeneuve, 371 Avenue du Doyen Gaston Giraud, 
34295 Montpellier Cedex 5, France. 
Acknowledgements
Member of the dissemination of MASK in 20 countries: J. Bousquet, P. Hellings, 
A. Bedbrook, C. Bachert, K.C. Bergmann, M. Bewick, C. Bindslev‑Jensen, S. 
Bosnic‑Anticevitch, D. Caimmi, P.A.M. Camargos, G.W. Canonica, T. Casale, N.H. 
Chavannes, A.A. Cruz, G. De Carlo, R. Dahl, P. Demoly, P. Devillier, J. Fonseca, 
W.J. Fokkens, T. Haahtela, J. Just, L. Klimek, P. Kuna, D. Larenas‑Linnemann, M. 
Morais‑Almeida, J. Mullol, R. Murray, R. Naclerio, R.E. O’Hehir, N.G. Papadopou‑
los, P. Potter, D. Ryan, B. Samolinski, H.J. Schunemann, A. Sheikh, F.E.R. Simons, 
P.V. Tomazic, A. Valiulis, E. Valovirta, M. Wickman, A. Yorgancioglu, T. Zuberbier, S. 
Arnavielle, G. De Vries, G. Dray, M. van Eerd.
Twinning of MASK in Reference Sites of the European Innovation Partner‑
ship on Active and Healthy Ageing: J. Bousquet, A. Bedbrook, M. Bewick, C. 
Bindslev‑Jensen, C. Bucca, D. Caimmi, N.H. Chavannes, P. Demoly, J. Fonseca, 
N.A. Guldemond, M. Illario, P. Kuna, M. Morais‑Almeida, J. Mullol, R. Murray, C. 
Stellato, A. Todo‑Bom, M.T. Ventura, I. Young, A. Yorgancioglu, S. Arnavielle, E. 
Ellers, J. Farrell, R. Gerth van Wick, Z. Gutter, G. Iaccarino, M. Olive‑Elias.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Obtained from all authors.
Ethics approval and consent to participate
Review, none needed.
Funding
European Innovation Partnership on Active and Healthy Ageing Reference Site 
MACVIA‑France, EU Structural and Development Fund Languedoc‑Roussillon, 
ARIA.
Received: 10 November 2016   Accepted: 5 December 2016
References
 1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis 
and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 
Suppl):S147–334.
 2. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: develop‑
ing guidelines. BMJ. 1999;318(7183):593–6.
 3. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. 
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in col‑
laboration with the World Health Organization, GA(2)LEN and AllerGen). 
Allergy. 2008;63(Suppl 86):8–160.
 4. Brozek JL, Akl EA, Alonso‑Coello P, Lang D, Jaeschke R, Williams JW, 
et al. Grading quality of evidence and strength of recommendations 
in clinical practice guidelines. Part 1 of 3. An overview of the GRADE 
approach and grading quality of evidence about interventions. Allergy. 
2009;64(5):669–77.
 5. Brozek JL, Baena‑Cagnani CE, Bonini S, Canonica GW, Rasi G, van Wijk RG, 
et al. Methodology for development of the Allergic Rhinitis and its Impact 
on Asthma guideline 2008 update. Allergy. 2008;63(1):38–46.
 6. Brozek JL, Bousquet J, Baena‑Cagnani CE, Bonini S, Canonica GW, Casale 
TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 
2010 revision. J Allergy Clin Immunol. 2010;126(3):466–76.
 7. Padjas A, Kehar R, Aleem S, Mejza F, Bousquet J, Schunemann HJ, et al. 
Methodological rigor and reporting of clinical practice guidelines in 
patients with allergic rhinitis: QuGAR study. J Allergy Clin Immunol. 
2014;133(3):777–783.e4.
 8. Bousquet J, Schunemann HJ, Samolinski B, Demoly P, Baena‑Cagnani 
CE, Bachert C, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): 
achievements in 10 years and future needs. J Allergy Clin Immunol. 
2012;130(5):1049–62.
 9. Bousquet J, Schunemann HJ, Fonseca J, Samolinski B, Bachert C, 
Canonica GW, et al. MACVIA‑ARIA Sentinel NetworK for allergic rhinitis 
(MASK‑rhinitis): the new generation guideline implementation. Allergy. 
2015;70(11):1372–92.
 10. Bousquet J, Michel J, Standberg T, Crooks G, Iakovidis I, Gomez M. The 
European Innovation Partnership on Active and Healthy Ageing: the 
European Geriatric Medicine introduces the EIP on AHA Column. Eur 
Geriatr Med. 2014;5(6):361–2.
 11. Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A, et al. Inte‑
grated care pathways for airway diseases (AIRWAYS‑ICPs). Eur Respir J. 
2014;44(2):304–23.
 12. Bousquet J, Barbara C, Bateman E, Bel E, Bewick M, Chavannes N, et al. 
AIRWAYS ICPs (European Innovation Partnership on Active and Healthy 
Ageing) from concept to implementation. Eur Respir J. 2016;47(4):1028–
33. doi: 10.1183/13993003.01856‑2015.
 13. Bousquet J, Anto JM, Berkouk K, Gergen P, Antunes JP, Auge P, et al. 
Developmental determinants in non‑communicable chronic diseases 
and ageing. Thorax. 2015;70(6):595–7.
 14. Bousquet J, Barbara C, Bateman E, Bel E, Bewick M, Chavannes NH, 
et al. AIRWAYS‑ICPs (European Innovation Partnership on Active 
and Healthy Ageing) from concept to implementation. Eur Respir J. 
2016;47(4):1028–33.
 15. Bousquet J, Farrell J, Crooks G, Hellings P, Bel E, Bewick M, et al. Scal‑
ing up strategies of the Chronic Respiratory Disease programme of 
the European Innovation Partnership on Active and Healthy Ageing 
(Action Plan B3—Area 5). Clin Transl Allergy. 2016;6:29. doi:10.1186/
s13601‑016‑0116‑9.
 16. Bousquet J, Dahl R, Khaltaev N. Global alliance against chronic respiratory 
diseases. Allergy. 2007;62(3):216–23.
 17. TRM Glossary. One‑VA technical reference model v14.10. US Department 
of Veteran Affairs. http://www.vagov/trm/TRMGlossaryPageasp. 2014.
 18. National Center for Complementary and Alternative Medicine (NCCAM). 
National Institutes of Health. Clinical practice guidelines. http://nccam.
nih.gov/health/providers/clinicalpractice.htm. 2014.
 19. Zander K. Historical development of outcomes‑based care delivery. Crit 
Care Nurs Clin N Am. 1998;10(1):1–11.
Page 13 of 14Bousquet et al. Clin Transl Allergy  (2016) 6:47 
 20. Campbell H, Hotchkiss R, Bradshaw N, Porteous M. Integrated care path‑
ways. BMJ. 1998;316(7125):133–7.
 21. Overill S. A practical guide to care pathways. J Integr Care. 1998;2:93–8.
 22. Integrated Care Pathways users in Scotland (ICPUS). A workbook for 
people starting to develop integrated care pathways. http://www.icpus.
org.uk2007.
 23. How to produce and evaluate an integrated care pathway (ICP): information 
for staff. Great Ormond Street Hospital for Children. www.gosh.nhs.uk. 2010.
 24. ARIA in the pharmacy: management of allergic rhinitis symptoms 
in the pharmacy. Allergic rhinitis and its impact on asthma. Allergy. 
2004;59(4):373–87.
 25. Bousquet J, Neukirch F, Bousquet PJ, Gehano P, Klossek JM, Le Gal M, 
et al. Severity and impairment of allergic rhinitis in patients consulting in 
primary care. J Allergy Clin Immunol. 2006;117(1):158–62.
 26. Bousquet J, Annesi‑Maesano I, Carat F, Leger D, Rugina M, Pribil C, et al. 
Characteristics of intermittent and persistent allergic rhinitis: DREAMS 
study group. Clin Exp Allergy. 2005;35(6):728–32.
 27. Bousquet PJ, Devillier P, Tadmouri A, Mesbah K, Demoly P, Bousquet J. 
Clinical relevance of cluster analysis in phenotyping allergic rhinitis in a 
real‑life study. Int Arch Allergy Immunol. 2015;166(3):231–40.
 28. del Cuvillo A, Montoro J, Bartra J, Valero A, Ferrer M, Jauregui I, et al. 
Validation of ARIA duration and severity classifications in Spanish allergic 
rhinitis patients—the ADRIAL cohort study. Rhinology. 2010;48(2):201–5.
 29. Jauregui I, Davila I, Sastre J, Bartra J, del Cuvillo A, Ferrer M, et al. Valida‑
tion of ARIA (Allergic Rhinitis and its Impact on Asthma) classification 
in a pediatric population: the PEDRIAL study. Pediatr Allergy Immunol. 
2011;22(4):388–92.
 30. Cruz AA, Popov T, Pawankar R, Annesi‑Maesano I, Fokkens W, Kemp J, 
et al. Common characteristics of upper and lower airways in rhinitis 
and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy. 
2007;62(Suppl 84):1–41.
 31. Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey 
of the burden of allergic rhinitis in Europe. Allergy. 2007;62(Suppl 
85):17–25.
 32. Bousquet PJ, Demoly P, Devillier P, Mesbah K, Bousquet J. Impact of aller‑
gic rhinitis symptoms on quality of life in primary care. Int Arch Allergy 
Immunol. 2013;160(4):393–400.
 33. Price D, Scadding G, Ryan D, Bachert C, Canonica GW, Mullol J, et al. The 
hidden burden of adult allergic rhinitis: UK healthcare resource utilisation 
survey. Clin Transl Allergy. 2015;5:39.
 34. Expert Panel Report 3 (EPR‑3): guidelines for the diagnosis and man‑
agement of asthma‑summary report 2007. J Allergy Clin Immunol. 
2007;120(5 Suppl):S94–138.
 35. O’Byrne PM, Reddel HK, Eriksson G, Ostlund O, Peterson S, Sears MR, et al. 
Measuring asthma control: a comparison of three classification systems. 
Eur Respir J. 2010;36(2):269–76.
 36. Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, et al. A 
summary of the new GINA strategy: a roadmap to asthma control. Eur 
Respir J. 2015;46(3):622–39. doi:10.1183/13993003.00853‑2015.
 37. Bousquet J, Bourquin C, Augé P, Domy P, Bringer J, Camuzat T, et al. 
MACVIA‑LR Reference Site of the European Innovation Partnership on 
Active and Healthy Ageing. Eur Geriatr Med. 2014;5(6):406–15.
 38. Bourret R, Bousquet J, Mercier J, Camuzat T, Bedbrook A, Demoly P, et al. 
MASK rhinitis, a single tool for integrated care pathways in allergic rhinitis. 
World Hosp Health Serv. 2015;51(3):36–9.
 39. Bousquet J, Bachert C, Canonica GW, Mullol J, Van Cauwenberge P, 
Bindslev Jensen C, et al. Efficacy of desloratadine in intermittent allergic 
rhinitis: a GALEN study. Allergy. 2009;64:1516–23.
 40. Bousquet J, Bachert C, Canonica GW, Mullol J, Van Cauwenberge P, Jensen 
CB, et al. Efficacy of desloratadine in persistent allergic rhinitis—a GA(2)
LEN study. Int Arch Allergy Immunol. 2010;153(4):395–402.
 41. Morais‑Almeida M, Santos N, Pereira AM, Branco‑Ferreira M, Nunes C, 
Bousquet J, et al. Prevalence and classification of rhinitis in preschool 
children in Portugal: a nationwide study. Allergy. 2013;68(10):1278–88.
 42. Morais‑Almeida M, Pite H, Pereira AM, Todo‑Bom A, Nunes C, Bousquet J, 
et al. Prevalence and classification of rhinitis in the elderly: a nationwide 
survey in Portugal. Allergy. 2013;68(9):1150–7.
 43. Klimek L, Bachert C, Mosges R, Munzel U, Price D, Virchow JC, et al. 
Effectiveness of MP29‑02 for the treatment of allergic rhinitis in 
real‑life: results from a noninterventional study. Allergy Asthma Proc. 
2015;36(1):40–7.
 44. Ohta K, Bousquet PJ, Aizawa H, Akiyama K, Adachi M, Ichinose M, et al. 
Prevalence and impact of rhinitis in asthma. SACRA, a cross‑sectional 
nation‑wide study in Japan. Allergy. 2011;66(10):1287–95.
 45. Larenas‑Linnemann D, Dinger H, Shah‑Hosseini K, Michels A, Mosges 
R. Over diagnosis of persistent allergic rhinitis in perennial allergic 
rhinitis patients: a nationwide study in Mexico. Am J Rhinol Allergy. 
2013;27(6):495–501.
 46. Shao J, Cui YX, Zheng YF, Peng HF, Zheng ZL, Chen JY, et al. Efficacy and 
safety of sublingual immunotherapy in children aged 3–13 years with 
allergic rhinitis. Am J Rhinol Allergy. 2014;28(2):131–9.
 47. Wei H, Zhang Y, Shi L, Zhang J, Xia Y, Zang J, et al. Higher dosage of HIFU 
treatment may lead to higher and longer efficacy for moderate to severe 
perennial allergic rhinitis. Int J Med Sci. 2013;10(13):1914–20.
 48. Tatar EC, Surenoglu UA, Saylam G, Isik E, Ozdek A, Korkmaz H. Is there 
any correlation between the results of skin‑prick test and the severity of 
symptoms in allergic rhinitis? Am J Rhinol Allergy. 2012;26(1):e37–9.
 49. Bousquet PJ, Bousquet‑Rouanet L, Co Minh HB, Urbinelli R, Allaert FA, 
Demoly P. ARIA (Allergic Rhinitis and Its Impact on Asthma) classification 
of allergic rhinitis severity in clinical practice in France. Int Arch Allergy 
Immunol. 2007;143(3):163–9.
 50. Rouve S, Didier A, Demoly P, Jankowsky R, Klossek JM, Anessi‑Maesano 
I. Numeric score and visual analog scale in assessing seasonal allergic 
rhinitis severity. Rhinology. 2010;48(3):285–91.
 51. Baiardini I, Braido F, Brandi S, Tarantini F, Bonini S, Bousquet PJ, et al. The 
impact of GINA suggested drugs for the treatment of asthma on health‑
related quality of life: a GA(2)LEN review. Allergy. 2008;63(8):1015–30.
 52. Yamamoto H, Yamada T, Sakashita M, Kubo S, Susuki D, Tokunaga T, et al. 
Efficacy of prophylactic treatment with montelukast and montelukast 
plus add‑on loratadine for seasonal allergic rhinitis. Allergy Asthma Proc. 
2012;33(2):e17–22.
 53. Bousquet PJ, Bachert C, Canonica GW, Casale TB, Mullol J, Klossek JM, et al. 
Uncontrolled allergic rhinitis during treatment and its impact on quality 
of life: a cluster randomized trial. J Allergy Clin Immunol. 2010;126(3):666–
668.e1‑5.
 54. Demoly P, Bousquet PJ, Mesbah K, Bousquet J, Devillier P. Visual 
analogue scale in patients treated for allergic rhinitis: an observational 
prospective study in primary care: asthma and rhinitis. Clin Exp Allergy. 
2013;43(8):881–8.
 55. Bousquet PJ, Combescure C, Klossek JM, Daures JP, Bousquet J. Change 
in visual analog scale score in a pragmatic randomized cluster trial of 
allergic rhinitis. J Allergy Clin Immunol. 2009;123(6):1349–54.
 56. Vuurman EF, Vuurman LL, Lutgens I, Kremer B. Allergic rhinitis is a risk fac‑
tor for traffic safety. Allergy. 2014;69(7):906–12.
 57. Hellgren J, Cervin A, Nordling S, Bergman A, Cardell LO. Aller‑
gic rhinitis and the common cold–high cost to society. Allergy. 
2010;65(6):776–83.
 58. Zuberbier T, Lotvall J, Simoens S, Subramanian SV, Church MK. Economic 
burden of inadequate management of allergic diseases in the European 
Union: a GA(2) LEN review. Allergy. 2014;69(10):1275–9.
 59. Lamb CE, Ratner PH, Johnson CE, Ambegaonkar AJ, Joshi AV, Day D, et al. 
Economic impact of workplace productivity losses due to allergic rhinitis 
compared with select medical conditions in the United States from an 
employer perspective. Curr Med Res Opin. 2006;22(6):1203–10.
 60. Walker S, Khan‑Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal 
allergic rhinitis is associated with a detrimental effect on examination 
performance in United Kingdom teenagers: case‑control study. J Allergy 
Clin Immunol. 2007;120(2):381–7.
 61. Nolte H, Nepper‑Christensen S, Backer V. Unawareness and undertreat‑
ment of asthma and allergic rhinitis in a general population. Respir Med. 
2006;100(2):354–62.
 62. Bousquet J, Schunemann HJ, Hellings PW, Arnavielhe S, Bachert C, 
Bedbrook A, et al. MACVIA clinical decision algorithm in adolescents and 
adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367–374.
e2. doi:10.1016/j.jaci.2016.03.025.
 63. Konig HH, Bernert S, Angermeyer MC, Matschinger H, Martinez M, Vilagut 
G, et al. Comparison of population health status in six european coun‑
tries: results of a representative survey using the EQ‑5D questionnaire. 
Med Care. 2009;47(2):255–61.
 64. Smith AF, Pitt AD, Rodruiguez AE, Alio JL, Marti N, Teus M, et al. The 
economic and quality of life impact of seasonal allergic conjunctivitis in a 
Spanish setting. Ophthalmic Epidemiol. 2005;12(4):233–42.
Page 14 of 14Bousquet et al. Clin Transl Allergy  (2016) 6:47 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 65. Blanc PD, Trupin L, Eisner M, Earnest G, Katz PP, Israel L, et al. The work 
impact of asthma and rhinitis: findings from a population‑based survey. J 
Clin Epidemiol. 2001;54(6):610–8.
 66. Bousquet J, Bodez T, Gehano P, Klossek JM, Liard F, Neukirch F, et al. 
Implementation of guidelines for allergic rhinitis in specialist practices. 
A randomized pragmatic controlled trial. Int Arch Allergy Immunol. 
2009;150(1):75–82.
 67. Ohta K, Jean Bousquet P, Akiyama K, Adachi M, Ichinose M, Ebisawa M, 
et al. Visual analog scale as a predictor of GINA‑defined asthma control. 
The SACRA study in Japan. J Asthma. 2013;50(5):514–21.
 68. Hojo M, Ohta K, Iikura M, Mizutani T, Hirashima J, Sugiyama H. Clini‑
cal usefulness of a guideline‑based screening tool for the diagnosis of 
allergic rhinitis in asthmatics: the Self Assessment of Allergic Rhinitis and 
Asthma questionnaire. Respirology. 2013;18(6):1016–21.
 69. Sullivan PW, Smith KL, Ghushchyan VH, Globe DR, Lin SL, Globe G. 
Asthma in USA: its impact on health‑related quality of life. J Asthma. 
2013;50(8):891–9.
 70. van der Leeuw S, van der Molen T, Dekhuijzen PN, Fonseca JA, van 
Gemert FA, Gerth van Wijk R, et al. The minimal clinically important dif‑
ference of the control of allergic rhinitis and asthma test (CARAT): cross‑
cultural validation and relation with pollen counts. NPJ Prim Care Respir 
Med. 2015;25:14107.
 71. Ciprandi G, Schiavetti I, Sorbello V, Ricciardolo FL. Perception of asthma 
symptoms as assessed on the visual analog scale in subjects with asthma: 
a real‑life study. Respir Care. 2016;61(1):23–9.
 72. Belgrave DC, Buchan I, Bishop C, Lowe L, Simpson A, Custovic A. Tra‑
jectories of lung function during childhood. Am J Respir Crit Care Med. 
2014;189(9):1101–9.
 73. Bousquet J, Anto J, Sunyer J, Nieuwenhuijsen M, Vrijheid M, Keil T, et al. 
Pooling birth cohorts in allergy and asthma: European Union‑funded 
initiatives—a MeDALL, CHICOS, ENRIECO, and GA(2)LEN joint paper. Int 
Arch Allergy Immunol. 2013;161(1):1–10.
 74. Anto JM, Pinart M, Akdis M, Auffray C, Bachert C, Basagana X, et al. 
Understanding the complexity of IgE‑related phenotypes from child‑
hood to young adulthood: a Mechanisms of the Development of Allergy 
(MeDALL) seminar. J Allergy Clin Immunol. 2012;129(4):943–954.e4.
 75. Bousquet J, Anto J, Auffray C, Akdis M, Cambon‑Thomsen A, Keil 
T, et al. MeDALL (Mechanisms of the Development of ALLergy): an 
integrated approach from phenotypes to systems medicine. Allergy. 
2011;66(5):596–604.
 76. Bousquet J, Anto JM, Akdis M, Auffray C, Keil T, Momas I, et al. Paving 
the way of systems biology and precision medicine in allergic diseases: 
the MeDALL success story. Allergy. 2016;71(11):1513–25. doi:10.1111/
all.12880.
 77. Ballardini N, Bergstrom A, Wahlgren CF, van Hage M, Hallner E, Kull I, et al. 
IgE antibodies in relation to prevalence and multimorbidity of eczema, 
asthma, and rhinitis from birth to adolescence. Allergy. 2016;71(3):342–9.
 78. Gabet S, Just J, Couderc R, Bousquet J, Seta N, Momas I. Early polysen‑
sitisation is associated to allergic multimorbidity in PARIS birth cohort 
infants. Pediatr Allergy Immunol. 2016;27(8):831–37. doi:10.1111/
pai.12622.
 79. Burte E, Bousquet J, Varraso R, Gormand F, Just J, Matran R, et al. 
Characterization of rhinitis according to the asthma status in adults 
using an unsupervised approach in the EGEA study. PLoS ONE. 
2015;10(8):e0136191.
 80. Siroux V, Lupinek C, Resch Y, Curin M, Just J, Keil T, et al. Specific IgE 
and IgG measured by the MeDALL allergen‑chip depend on allergen 
and route of exposure: the EGEA study. J Allergy Clin Immunol. 2016. 
doi:10.1016/j.jaci.2016.05.023.
 81. Just J, Elegbede CF, Deschildre A, Bousquet J, Moneret‑Vautrin DA, Crepet 
A, et al. Three peanut allergic/sensitized phenotypes with gender differ‑
ence. Clin Exp Allergy. 2016;46(12):1596–1604. doi:10.1111/cea.12791.
 82. Bresciani M, Paradis L, Des Roches A, Vernhet H, Vachier I, Godard 
P, et al. Rhinosinusitis in severe asthma. J Allergy Clin Immunol. 
2001;107(1):73–80.
 83. ten Brinke A, Grootendorst DC, Schmidt JT, De Bruine FT, van Buchem 
MA, Sterk PJ, et al. Chronic sinusitis in severe asthma is related to sputum 
eosinophilia. J Allergy Clin Immunol. 2002;109(4):621–6.
 84. ten Brinke A, Sterk PJ, Masclee AA, Spinhoven P, Schmidt JT, Zwinder‑
man AH, et al. Risk factors of frequent exacerbations in difficult‑to‑treat 
asthma. Eur Respir J. 2005;26(5):812–8.
 85. Wilson N, Bewick M, Dziworski W. Maintaining health despite chronic ill‑
ness in the elderly: a multi‑disciplinary study visit to the north of England 
region. Eur Geriatr Med. 2015;6(4):396–400.
